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Background: Impairment of cochlear blood flow has often
been considered as the common final pathway of various
inner ear pathologies. TNF, an ubiquitous cytokine, plays a
major role in these pathologies, reducing cochlear blood flow
via sphingosine-1-phosphate-signaling.
Methods: Fifteen Dunkin-Hartley guinea pigs were randomly
assigned to one of three groups (placebo/placebo, TNF/
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Results: Treatment with TNF led to a significant decrease of
cochlear blood flow.
Following this, application of placebo caused no significant
changes while application of FTY-720 caused a significant
rise in cochlear blood flow.
Conclusions: FTY-720 is capable of reversing changes in
cochlear blood flow induced by application of TNF. This
makes FTY-720 a valid candidate for potential treatment
of numerous inner ear pathologies. Key Words: Cochlear
blood flow—Fingolimod—Microcirculation—Tumor necrosis
factor.
Otol Neurotol 38:1213–1216, 2017.Local microcirculation is a critical parameter for
cochlear function. Impairment of microcirculation
results in decreases in partial oxygen pressure (1) and
subsequent loss of function, including significant
decreases in endocochlear potential and increases in
hearing thresholds (2–4). Impairment and regulation
of cochlear microcirculation also plays a role in thepathophysiology and treatment of other pathologies
such as Menière’s disease (5) and inflammatory inner
ear pathologies (3,6).
Tumor necrosis factor (TNF) is an ubiquitous cytokine
that is involved in various types of disease, including, but
not limited to malignancies (7), autoimmune diseases (8),
and depression (9). It has also been established that TNF
is capable of impairing local circulation in various tis-
sues, including the cochlea (6,10). Moreover, several
studies have been able to demonstrate that TNF is
involved in a number of inner ear pathologies, such as
sudden sensorineural hearing loss (6), acoustic (3), and
physical trauma (11).
Research has shown that the effects of TNF are
mediated by several pathways (12): after binding to its
specific receptor, TNF amplifies intracellular signaling
pathways that lead to induction of cell death, including
NFkB- and JNK-signaling as well as caspases. TNF also
activates sphingosine-1-phosphate signaling (6). Overall,
the short-term effects of TNF related pathologies are
mediated by sphingosine-1-phosphate signaling (6) while
the long-term effects are instead mediated by intracellu-
lar signaling leading to cell death, including NFkB- and
JNK-signaling (13).horized reproduction of this article is prohibited.
(22). An exact description with sample pictures of the digital
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term effects of TNF on cochlear microcirculation have
either not been specific to sphingosine-1-phosphate sig-
naling (14) or have been experimental and have not been
approved for human use (6). However, since 2010,
Fingolimod (FTY-720), a sphingosine-1-phosphate ana-
logue that is sold under the name Fingolimod has been
approved for clinical use in human patients suffering
from multiple sclerosis (15,16). Upon binding the sphin-
gosine-1-phosphate receptor, it is actively transported
into the expressing cell and thus cannot be activated
anymore (17,18). Hence, we examined the potential of
FTY-720 to reverse changes in cochlear microcirculation
induced by topical application of TNF.
MATERIALS AND METHODS
Ethics Statement
All experiments were performed according to local state
regulations and approved by the responsible authorities (Nie-
dersächsisches Landesamt für Verbraucherschutz und Leben-
smittelsicherheit LAVES) under the animal license no: 33.9–
42502–04–14/1427.
Animals
Animals were Dunkin-Hartley guinea pigs bred for experi-
mental use and purchased from Harlan Laboratories (Ober-
Ramstadt, Hesse, Germany), weighing 200 to 450 g. Anesthesia
was induced by an intraperitoneal injection of 50 mg/kg body-
weight (b.w.) ketamine and 5 mg/kg b.w. xylazine and sustained
by repeated intramuscular injections of 25 mg/kg b.w. ketamine
and 2.5 mg/kg b.w. xylazine every 30 minutes.
Surgical preparation lasted approximately 60 to 90 minutes.
After the experiments were conducted, animals were eutha-
nized by an overdose of anesthesia and subsequent cervical
dislocation.
Surgical Approach
The technique applied in this experiment has been previously
described (19–21). After induction of anesthesia, a cervical
venous catheter was surgically implemented. Subsequently, the
external ear and the temporal bone covering the bulla were
removed, thus exposing the cochlea. Overlying periosteal ves-
sels were carefully removed using a microsponge. As soon as
all the vessels were removed, a rectangular window was carved
into the cochlea above the second turn, exposing the stria
vascularis. Finally, fluorescein-labeled dextrane (molecular
weight 500,000; 0.05–0.1 ml of a 5% solution in 0.9% NaCl;
Sigma–Aldrich, Deisenhofen, Germany) was applied intrave-
nously, allowing direct visualization of intravascular blood flow
in the stria vascularis, with a contrast between erythrocytes and
plasma. Following illumination with a Leica EL6000 light
source (Leica Microsystems, Wetzlar, Germany), images were
obtained with a Leica M205 FA stereomicroscope. The propri-
etary Leica Application Suite software was then used to process
and save the generated data for later off-line analysis.
An example of the video material acquired is available
with the supplementary digital content (http://links.lww.com/
MAO/A538).
Velocity (micrometers per second) and diameter (micro-
meters) of stria vascularis vessels were quantified using Cap-
Image (Dr. Zeintl Biomedical Engineering, Heidelberg,
Germany), a software specifically designed for this purposeCopyright © 2017 Otology & Neurotology, Inc. Unauthorized
Otology & Neurotology, Vol. 38, No. 8, 2017quantification of intravascular blood velocity is also available
with the supplementary digital content (http://links.lww.com/
MAO/A539).
For each vessel the intravascular blood flow was calculated
with a formula proposed by Wayland: q¼ (v/1.6) (d/2)2p
(23). To correct for interindividual differences as well as
differences between individual vessels, units are reported as
arbitrary units (AU), representing change from the initially
acquired basal values.
Treatment Protocol
Five animals were randomly assigned to one of three groups
(placebo/placebo, TNF/placebo, or TNF/FTY-720). After the
surgical preparation and before treatment had begun, basal
images were acquired for later analysis. Following this, placebo
or TNF was applied topically for 20 minutes. Afterwards, the
bulla was rinsed with 0.9% saline solution for 10 minutes and
the microcirculation was quantified again. Then, placebo or
FTY-720 was applied for 20 minutes and the bulla was washed
again before final images were acquired. Similar protocols
have been used in previous experiments addressing this topic
(10,14). After the protocol had been finished, the animals were
euthanized.
For placebo, a sterile saline solution was chosen. The con-
centration of TNF was 5.0 ng/ml in sterile saline solution as
reported in previous experiments (10,14). For the FTY-720
solution, 1 mg of FTY-720 was dissolved in 5 ml of dimethyl
sulfoxide, resulting in a concentration of 200 mg/ml. This was
then diluted 1:10 in sterile saline solution, resulting in a final
concentration of 20 mg/ml FTY-720 which was then applied.
Statistics
Statistical analysis was carried out using Project R (Build
3.3.2 for Windows, The R Project for Statistical Computing,
http://www.r-project.org/). To detect differences between the
groups as well as between the timepoints within the groups, we
used a Wilcoxon test. This test allows paired and unpaired two-
sample nonparametric comparisons. We used a Bonferroni
correction to adjust for multiple testing, thus a p value of a
<0.005 was considered to be statistically significant.
RESULTS
Effect of Placebo R Placebo on Cochlear Blood Flow
The initial topical application of placebo leads to
no significant changes in cochlear blood flow, which
remained steady at 1.01 0.06 AU (Fig. 1, left column).
Subsequent application of placebo leads to a drop in
cochlear blood flow to 0.92 0.09 AU. There were no
significant differences within the group (Table 1). The
values acquired after the first treatment with placebo
were significantly different from those values obtained
after treatment with TNF (Table 2).
Effect of TNF R Placebo on Cochlear Blood Flow
Initial application of TNF led to a drop in cochlear
blood flow to .81 .07 AU (Fig. 1, middle column). This
was significantly different from the basal values as well
as compared with placebo (Tables 1 and 2). Subsequent
application of placebo induced no change in cochlear
blood flow, which remained steady at 0.81 0.10 AU. reproduction of this article is prohibited.
FIG. 1. Relative changes in cochlear blood flow over time, before
initial treatment, in between treatments and after final treatment,
reported in arbitrary units (AU).
TABLE 2. p Values for the comparions of groups within time
points. Values marked bold were considered significant
Treatment 1 Treatment 2
Placebo/placebo versus TNF/placebo p¼ 0.005
TNF/placebo versus TNF/FTY-720 p< 0.001a p< 0.001
Placebo/placebo versus TNF/FTY-720 p¼ 0.539
aThe animals of the TNF/placebo and the TNF/FTY-720 group at
Treatment 1 were pooled and compared against the animals that had
received placebo, since the treatment both groups had received was
biologically the same.
FTY-720 indicates Fingolimod; TNF, tumor necrosis factor.
FINGOLIMOD ABROGATES EFFECTS OF TNF ON COCHLEAR BLOOD FLOW 1215This value was significantly different from the initial
acquired basal value as well as the final values measured
after application of TNF and subsequently FTY-720,
but not significantly different from the values obtained
within the same group after initial TNF application
(Tables 1 and 2).
Effect of TNF R FTY-720 on Cochlear Blood Flow
Again, initial application of TNF caused a significant
drop in cochlear blood flow to 0.83 0.06 AU (Fig. 1,
right column; Tables 1 and 2). Subsequent application of
FTY-720 caused an increase in cochlear blood flow to
0.94 0.07 AU. This increase was significantly different
from the previously obtained values within this group
(Table 1) as well as significantly different from the
endpoint of the group that was treated with TNF and
subsequently placebo, but not different from the values
that were obtained in the group after the twofold appli-
cation of placebo (Table 2).
DISCUSSION
In this study we confirmed that TNF decreases cochle-
ar blood flow after topical application. This finding is inCopyright © 2017 Otology & Neurotology, Inc. Unaut
TABLE 1. p Values for the comparisons of time points in











Placebo/placebo p¼ 0.561 p¼ 0.010 p¼ 0.005
TNF/placebo p< 0.001 p< 0.001 p¼ 1.000
TNF/FTY-720 p< 0.001 p¼ 0.013 p< 0.001
FTY-720 indicates Fingolimod; TNF, tumor necrosis factor.line with previous reports (6). Moreover, it has been
reported that the effect of TNF is dose-dependent (14). It
was previously also demonstrated that the effects of TNF
on cochlear blood flow could be reversed by blocking the
TNF receptor with etanercept (6,14). Etanercept has, so
far, been shown to have beneficial effects in various
cochlear pathologies that coincide with impairments of
cochlear blood flow, including sudden sensorineural
hearing loss (6) or acoustic trauma (3).
We demonstrated that topical application of FTY-720
is able to reverse the effects of TNF on cochlear blood
flow: application of FTY-720 caused a significant in-
crease in cochlear blood flow. The fact that the cochlear
blood flow had also decreased somewhat in the group that
had received a placebo twice could be explained by
increased clotting in the capillaries caused by the surgical
manipulation, a phenomenon that has previously been
reported in this animal model (20). Even though this
could be a potential confounder in the animal model used
in this study, this also raises the threshold levels to obtain
significant results, assuming that FTY-720 would in-
crease cochlear blood flow compared with previous
values.
The effect of FTY-720 is most likely mediated by its
interaction with the sphingosine-1-phosphate-receptor. It
has been known to bind the receptor, causing it to be
transported into the inside of the cell, thus preventing it
from being activated (17). This viewpoint is supported by
the fact that blocking of the sphingosine-1-phosphate
receptor has been able to revoke typical effects of TNF
on microvasculature (6,10,24,25). Additionally, another
potential mode of action has to be taken into account:
FTY-720 has also been known to interact with the
cannabinoid CB1-receptor; more specifically as a com-
petitive CB-1-antagonist (26). It has been reported that
antagonism at the CB-1-receptor is capable of preventing
decreases in microcirculation caused by endotoxemia in
other tissues, specifically the small intestine (27). This
argument is further supported by the fact that endotox-
emia is thought to cause several complications involving
the TNF pathway and that blockage of the TNF-receptor
using etanercept significantly reduces the immediate
clinical effects of endotoxemia (28,29).
The presented results show that FTY-720 is capable of
reversing the effects of TNF on cochlear blood flow.
Assuming that alterations in cochlear blood flow cause ahorized reproduction of this article is prohibited.
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1216 M. BERTLICH ET AL.drop in partial oxygen pressure (1) and thus eventually
ischemia and subsequent apoptosis of inner hair cells,
FTY-720 might be a promising agent fit for clinical
testing in various inner ear pathologies, including sudden
sensorineural hearing loss (4,6), noise trauma (3), as well
as physical trauma to the cochlea (11). As an additional
benefit in comparison to other drugs that have been
suggested as treatments for these pathologies, such as
AM-111 (30) or JTE-013 (6), FTY-720 has already been
approved for clinical use in relapsing remitting multiple
sclerosis and, thus, has a well known safety profile.
Moreover, its route of administration (oral intake, once
daily) is significantly less complicated than the route of
administration of etanercept, which has also been sug-
gested as a potential treatment for these pathologies
(3,6,14) and which has to be applied by daily subcutane-
ous injections.
Common side-effects of FTY-720 include leukopenia
with the potential risk of opportunistic infections, brady-
cardia, elevation of liver enzymes, arterial hypertension,
and macular edema (31). Since the need of an observa-
tional period of 6 hours after the first intake and the need
of regular follow up examinations including frequent
control of liver enzymes and lymphocytes during therapy
with FTY-720, the intratympanic installation and subse-
quent crossing into the cochlea might be considered.
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